<?xml version="1.0" encoding="UTF-8"?>
<p>Molecular hybridisation is one of the effective chemotherapeutic agent production techniques that require the synthesis of two distinct bioactive units. In the present research, the design and synthesis of novel hybrid compounds bearing piperazine and chalcone or piperazine and pyrazoline (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) are our target. Newly synthesised compounds have been submitted for evaluation of their anticancer activity to the National Cancer Institute (NCI). Six compounds were selected by NCI, and 60 lines of human cancer cells were screened 
 <italic>inÂ vitro</italic>. The inhibitory activity had been also tested against VEGFR-2.
</p>
